Profit stands at Rs 758.8 crore Vs loss of Rs 6,511.2 crore. Revenue falls 3.25 to Rs 53,904.7 crore Vs Rs 55,681.9 crore
EBITDA spikes 43.9% to Rs 6,141.3 crore Vs Rs 4,267.8 crore. Margin expands 370 bps to 11.4% Vs 7.7%
Profit rises 0.3% to Rs 3,793 crore Vs Rs 3,781.4 crore. Revenue increases 0.09% to Rs 11,277.8 crore Vs Rs 11,267.1 crore. EBITDA falls 2.1% to Rs 9,701.3 crore Vs Rs 9,908.4 crore. Margin drops 190 bps to 86% Vs 87.9%
Profit zooms 59% to Rs 395.7 crore Vs Rs 248.8 crore. Revenue grows 15.3% to Rs 5,589.3 crore Vs Rs 4,846.9 crore. EBITDA jumps 30% to Rs 815.5 crore Vs Rs 627.5 crore. Margin expands 170 bps to 14.6% Vs 12.9%
Profit surges 40.8% to Rs 536.4 crore Vs Rs 381 crore. Revenue falls 19.3% to Rs 4,346.2 crore Vs Rs 5,385.5 crore. EBITDA zooms 28.5% to Rs 790.2 crore Vs Rs 615 crore. Margin expands 680 bps to 18.2% Vs 11.4%
Profit falls 6.92% to Rs 307 crore Vs Rs 329.8 crore. Revenue declines 15% to Rs 3,781.8 crore Vs Rs 4,450.3 crore. EBITDA drops 4% to Rs 514.2 crore Vs Rs 535.6 crore. Margin expands 160 bps to 13.6% Vs 12%
Net income drops 18% to $128 million. Net income excluding special items falls 1% to $179 million. Adjusted EBITDA declines 5% to $462 million. Rolled product shipments grow 1% to 945 kilotonnes
Profit zooms 32.9% to Rs 25.9 crore Vs Rs 19.5 crore. Revenue grows 13.3% to Rs 228.8 crore Vs Rs 202 crore
Profit plunges 61.1% to Rs 27 crore Vs Rs 69.4 crore. Revenue falls 28.1% to Rs 187.7 crore Vs Rs 261.1 crore
The pharma company announced the opening of its Qualified Institutions Placement (QIP) issue on November 6. The floor price for the issue has been set at Rs 1,162.25 per share.
Polycab has emerged as the lowest bidder for a contract worth Rs 1,549.66 crore from Bharat Sanchar Nigam Limited (BSNL). The contract involves the development of the middle-mile network of BharatNet on a Design, Build, Operate, and Maintain (DBOM) model for Package 7 (Bihar).
The company has signed a technical collaboration agreement with Kunshan GLVAC Yuantong New Energy Technology, a wholly owned subsidiary of China's Kunshan Guoli Electronic Technology. The collaboration is for manufacturing advanced high-voltage direct current (HVDC) contactors and relays in India.
The company has received a drug manufacturing license for its upcoming facility in Jammu, from the Government of Jammu and Kashmir.
Vikasdhan - Grow your Dhan with Vikasdhan
Disclaimer- not an investment advice, only for educational purpose. To read complete disclaimer, click on the link https://www.vikasdhan.com/disclaimer